William J. Bodell Ph.D.

I am a analytical biochemist with experience in the development and application of laboratory procedures, organic chemistry, HPLC, mass spectrometry, enzyme assays, in vivo tumor models and cell culture methods. Leadership experience developed through supervision of laboratory staff. Organizational and analysis skills acquired through analysis of laboratory results, statistical analysis of data and preparation of study reports.

Education

B.S.: Chemistry, University of Nebraska, Lincoln, NE

Ph.D.: Life Sciences, University of Nebraska, Lincoln, NE.

Key Skills:

• Project development and management in conjunction with writing abstracts, reports and manuscripts describing the results of the studies. Writing and submission of NIH and SBIR grants. Subject research and drafting of patent applications.

• Use of software for graphing data and preparation of figures for reports. Application of programs such as Marvin, and Chem-Draw for drawing chemical structures. Statistical analysis of data sets. Search Pub-Med and related online data banks for information related to either current or projects being developed.

• Development and optimization of HPLC methods for analyte detection and quantification. Use of a wide variety of detection methods including UV, electrochemical, fluorescence, radioisotope and mass spectrometry for analyte detection.

• Chemistry experience includes organic and biochemistry. Synthesis of modified nucleosides. Structural identification of prepared compounds with UV, NMR and mass spectrometry. Use of Micromass Quattro II triple quad mass spectrometer for identification and quantification of analytes. Use of Mass Lynx for control and data analysis. Synthesis of isotopic standards for analyte quantification by mass spectrometry. Biochemistry experience includes development and optimization of both radioactive and non radioactive methods and immunoassays. Column Chromatography and TLC purification methods. Ability to take methods reported in the literature and to establish them in laboratory.

• Detection and quantification of analytes with Agilent GC-MSD using Chemstation software. Derivatization of carbohydrates and lipids for separation and detection by GC-MS. Use of Agilent 1000 HPLC with autosampler and fraction collector for preparative collection of analytes

• Application of tissue culture methods to maintain and bank cell lines in culture and to set up experiments using specific human or rodent cell lines. Experience with a wide variety of primary and tumor human cell lines and in vivo tumor models Analysis of human and rodent tissue samples from preclinical and clinical trials.

Work Experience

Touro University (1/12-5/12) Position Post Doctoral Scientist

I performed MIDA (mass isotopomer distribution analysis) on clinical samples using GC-MS. These measurements were conducted to determine the increase in de novo lipogenesis in subjects fed a controlled diet. These measurements can be used for the analysis of the effects of various diets or therapeutic agents on metabolic processes such as glucose and fat production in human subjects.

Significant Accomplishment: Optimized a HPLC method for purification of acetaminophen-glucuronide conjugates from urine samples.

Contrast Therapeutics (2006-2011). Position: Founder : Chemist

A series of therapeutic agents were synthesized which are being investigated for their use in the treatment of human metastatic tumors. The compounds prepared were screened for their in vitro cytotoxicity and are undergoing additional investigations.

Significant Accomplishment: These newly developed agents are unique in that they have both therapeutic and imaging properties. The properties of these agents will allow for direct treatment of metastatic tumors and visualization of their distribution in tumors by clinical imaging technologies. Patents describing the properties and use of these compounds are being submitted.

University of California, San Francisco (1995-2006). Position: Adjunct Professor

Project Development: Initiated, developed and managed research programs on the treatment of malignant brain tumors, experimental therapeutics and toxicology. The support of these projects was from NIH grants.

Significant Accomplishment; Awarded over 4 million dollars from a combination of federal and state funding sources in support of these research projects.

Experimental Therapeutics: The focus of this program was the investigation of the mechanism(s) of action chemotherapeutic agents used in the treatment of brain tumors. In these studies, I developed a variety of analytical methods to quantify the levels of DNA adducts formed by clinically used chemotherapeutic agents. The level of DNA adducts were measured in laboratory samples, rodent models and in human tumor samples.

Significant Accomplishments: The levels of DNA adducts formed by the chemotherapeutic agent bis-(2-chloroethyl)-nitrosourea were quantified in experimental models and clinical samples. The development of LC/MS/MS methods for the quantification of DNA adducts allowed us to determine the levels and distribution of BCNU in human brain tumors following stereotactic injection. These studies lead to the development of multiple investigator initiated phase I and phase II clinical trials.

Toxicology: The structure(s) of the DNA adducts formed by the human carcinogens benzene and styrene and tamoxifen were identified. These studies were used to develop molecular biomarkers for estimating human exposure to these agents

Significant Accomplishments: Our studies were the first to demonstrate the formation of DNA adducts by the benzene metabolites p-benzoquinone, o- benzoquinone and 1,2,4-benzenetriol. Our investigations demonstrated that DNA adducts were formed in the blood mononuclear cells in workers occupationally exposed to styrene. These results were very important to defining occupational exposure levels to styrene.